IVVD
Invivyd, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.91
P/S
3.18
EV/EBITDA
1.03
DCF Value
$11.54
FCF Yield
-34.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.0%
Operating Margin
-104.0%
Net Margin
-98.2%
ROE
-48.7%
ROA
-19.0%
ROIC
-22.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $17.2M | $-11.1M | $-0.06 |
| FY 2025 | $53.4M | $-52.5M | $-0.30 |
| Q3 2025 | $13.1M | $-10.5M | $-0.06 |
| Q2 2025 | $11.8M | $-14.7M | $-0.12 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.74
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.